Lead sponsor
Asger Lund, MD
2 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
2
Trials led
0
Ongoing
73
Total enrollment
2
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Not applicable
2
Trials by status
Completed
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 DiabetesBMI 25-50not applicableCompleted61